Literature DB >> 26718106

Haematological cancer: Ibrutinib paves way to a brighter future in MCL.

David Killock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26718106     DOI： 10.1038/nrclinonc.2015.231

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

Authors:  Martin Dreyling; Wojciech Jurczak; Mats Jerkeman; Rodrigo Santucci Silva; Chiara Rusconi; Marek Trneny; Fritz Offner; Dolores Caballero; Cristina Joao; Mathias Witzens-Harig; Georg Hess; Isabelle Bence-Bruckler; Seok-Goo Cho; John Bothos; Jenna D Goldberg; Christopher Enny; Shana Traina; Sriram Balasubramanian; Nibedita Bandyopadhyay; Steven Sun; Jessica Vermeulen; Aleksandra Rizo; Simon Rule
Journal:  Lancet       Date:  2015-12-07       Impact factor: 79.321
  1 in total
  1 in total

1.  YouTube as a platform to better understand the treatment of lymphoma using ibrutinib: a cross-sectional study.

Authors:  Lin Yang; Xiuliang Qiu; Qiuling Zhao; Hongqiang Qiu; Yu Cheng; Wenbin Liu; Ruixiang Xie
Journal:  Ann Transl Med       Date:  2022-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.